Crown Bioscience and Turbine Partner to Connect AI-Driven Prediction with Organoid Validation in Translational Oncology
Crown Bioscience announced a strategic partnership with Turbine on April 21, 2026, to integrate Turbine’s in silico Virtual Assays with Crown’s Tumor Organoid Assays based on HUB Organoid Technology.
The collaboration creates a connected workflow for efficient hypothesis-to-validation in oncology research, simulating responses across thousands of samples and hundreds of drugs.
It forms a closed-loop system enhancing predictive accuracy, reducing experimental burden, costs, and timelines while improving biological relevance and clinical translatability.
Crown Bioscience uses ~1,000 tumor organoid models across 35 cancer indications; Turbine’s Virtual Lab explores millions of hypotheses in silico.
John Gu, CEO of Crown Bioscience, stated it improves decision-making confidence and accelerates clinic paths.
Szabolcs Nagy, CEO of Turbine, highlighted addressing the scale-translatability trade-off in drug discovery.